# Oova

> Oova is a New York-based women's health company that brings lab-grade hormone testing into the home. Founded in 2017 as a Mount Sinai spinout by Dr. Aparna (Amy) Divaraniya, Oova combines urine test strips, smartphone scanning, and AI to quantitatively measure LH, E3G (estrogen metabolite), and PdG (progesterone metabolite), giving women personalized daily insights for fertility, PCOS, cycle health, and perimenopause. The FDA-registered platform is used by consumers and integrated with hundreds of fertility and women's health clinics through a HIPAA-compliant provider dashboard.

- **Founded:** 2017
- **Headquarters:** New York, United States
- **Founders:** Aparna (Amy) Divaraniya (CEO & Founder), Jerome Scelza (Co-Founder)
- **Team size:** ~14 employees
- **Products:** Oova Fertility Hormone Kit, Oova Perimenopause Hormone Kit, Oova App, Oova Membership, Provider Dashboard
- **Notable:** Raised $13.7M+ total funding including a $10.3M Series A (2023), FDA-registered at-home hormone test measuring LH, E3G, and PdG, Integrated with 400+ fertility and women's health clinics

## Products & services

- **Oova Fertility Hormone Kit** — FDA-registered at-home urine test kit measuring LH and PdG (progesterone metabolite), scanned via smartphone app for quantitative daily fertility insights and ovulation confirmation.
- **Oova Perimenopause Hormone Kit** — At-home kit with a first-of-its-kind E3G estrogen biomarker plus LH/PdG tests and an app with real-time perimenopause stage tracking (launched at $159.99 with 30 tests).
- **Oova App** — AI-powered companion app that scans test strips with the phone camera, builds a personal hormone baseline, recognizes patterns, and delivers daily insights and cycle predictions.
- **Oova Membership** — Subscription model with discounted monthly test kits, 1:1 expert consultations, and community access.
- **Provider Dashboard** — HIPAA-compliant remote patient monitoring dashboard used by fertility and women's health clinics to track patients' hormone data between visits.
- **Oura Ring Integration** — Integration syncing Oura sleep and recovery data alongside daily hormone patterns and symptom tracking in the Oova app.

## Achievements

- Raised $13.7M+ total funding including a $10.3M Series A (2023)
- FDA-registered at-home hormone test measuring LH, E3G, and PdG
- Integrated with 400+ fertility and women's health clinics
- Algorithms trained on 30,000+ menstrual cycles
- Launched first-of-its-kind at-home perimenopause kit with E3G estrogen biomarker (2023)
- Published peer-reviewed research on hormone-based cycle-day prediction (Medicina, 2023)
- Reports a 46% increase in successful pregnancies among fertility patients
- Recognized by ASRM, ACOG, and The Menopause Society
- Backed by Virgin Group, Sara Blakely, Samsung Next, and US Fertility

## Latest updates

- **2025-09** — Announced hormone pattern technology identifying 15 distinct perimenopause hormone patterns from analysis of 30,000+ cycles, linking them to symptoms like hot flashes and insomnia.
- **2025-07** — Launched Oura Ring integration syncing sleep and recovery data with hormone and symptom tracking.
- **2025-04** — Featured in Forbes coverage of fertility and perimenopause innovation in women's health.
- **2024-10** — Released the State of Perimenopause 2024 Report and announced collaborations with Midi Health, Evernow, and Kindra.
- **2023-12** — Launched the at-home Perimenopause Hormone Kit with a first-of-its-kind E3G estrogen biomarker.
- **2023-06** — Closed $10.3M Series A led by Spero Ventures and launched the Oova Membership model.

## Links

- Website: https://oova.life
- LinkedIn: http://www.linkedin.com/company/oova-inc
- Twitter/X: https://twitter.com/OOVAlife
- Instagram: https://www.instagram.com/oovalife/
- Facebook: https://facebook.com/OOVAlife/

---

Profile page: https://yespress.io/oova
Published by YesPress — https://yespress.io
Last updated: 2026-07-18